JP2021522180A5 - - Google Patents

Info

Publication number
JP2021522180A5
JP2021522180A5 JP2020557256A JP2020557256A JP2021522180A5 JP 2021522180 A5 JP2021522180 A5 JP 2021522180A5 JP 2020557256 A JP2020557256 A JP 2020557256A JP 2020557256 A JP2020557256 A JP 2020557256A JP 2021522180 A5 JP2021522180 A5 JP 2021522180A5
Authority
JP
Japan
Prior art keywords
approximately
antibody preparation
sodium phosphate
buffered
formulation
Prior art date
Application number
JP2020557256A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522180A (ja
JPWO2019204380A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/027790 external-priority patent/WO2019204380A1/en
Publication of JP2021522180A publication Critical patent/JP2021522180A/ja
Publication of JP2021522180A5 publication Critical patent/JP2021522180A5/ja
Publication of JPWO2019204380A5 publication Critical patent/JPWO2019204380A5/ja
Pending legal-status Critical Current

Links

JP2020557256A 2018-04-17 2019-04-17 ベバシズマブの緩衝製剤を用いる疾患の治療方法 Pending JP2021522180A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862658772P 2018-04-17 2018-04-17
US62/658,772 2018-04-17
US201862776686P 2018-12-07 2018-12-07
US62/776,686 2018-12-07
PCT/US2019/027790 WO2019204380A1 (en) 2018-04-17 2019-04-17 Buffered formulations of bevacizumab for use of treating diseases

Publications (3)

Publication Number Publication Date
JP2021522180A JP2021522180A (ja) 2021-08-30
JP2021522180A5 true JP2021522180A5 (https=) 2022-04-22
JPWO2019204380A5 JPWO2019204380A5 (https=) 2022-04-22

Family

ID=66429576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020557256A Pending JP2021522180A (ja) 2018-04-17 2019-04-17 ベバシズマブの緩衝製剤を用いる疾患の治療方法

Country Status (12)

Country Link
US (1) US20210230261A1 (https=)
EP (1) EP3781199A1 (https=)
JP (1) JP2021522180A (https=)
KR (1) KR20210011923A (https=)
CN (1) CN112543645A (https=)
AU (1) AU2019256289A1 (https=)
BR (1) BR112020021255A2 (https=)
CA (1) CA3097123A1 (https=)
IL (1) IL278041A (https=)
MX (1) MX2020010968A (https=)
SG (1) SG11202010178XA (https=)
WO (1) WO2019204380A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20220149690A (ko) * 2020-03-04 2022-11-08 상하이 헨리우스 바이오테크, 인크. 베바시주맙을 포함하는 약물 조제용 제제
CN113546172A (zh) * 2020-04-24 2021-10-26 山东大学齐鲁医院 Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用
WO2022006091A1 (en) * 2020-06-29 2022-01-06 Anovent Pharmaceutical (U.S.), Llc Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
EP3861969A1 (en) * 2010-08-05 2021-08-11 ForSight Vision4, Inc. Injector apparatus for drug delivery
MX379491B (es) * 2014-06-28 2025-03-10 Kodiak Sciences Inc Antagonistas duales de factor de crecimiento derivado de plaquetas (pdgf)/factor de crecimiento endotelial vascular (vegf)
AU2016382786A1 (en) * 2015-12-29 2018-07-19 Outlook Therapeutics, Inc. Buffered formulations of bevacizumab
CN106924184B (zh) * 2017-03-29 2020-07-17 烟台大学 一种眼部玻璃体注射用多囊脂质体及其制备方法

Similar Documents

Publication Publication Date Title
JP2021522180A5 (https=)
CA3025258C (en) Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
Wong et al. Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit
US20060293270A1 (en) Methods and compositions for treating ocular disorders
US20240124538A1 (en) Modulation of Wnt5a to Treat Glaucoma
JP2019521156A5 (https=)
JPWO2019204380A5 (https=)
US20070027102A1 (en) Methods and compositions for treating macular degeneration
Moon et al. Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis
CN114929245A (zh) 用于治疗干性年龄相关性黄斑变性(amd)或继发于干性amd的地图样萎缩的抗c5剂
JP2022527276A (ja) 眼疾患を治療するための組成物及び方法
Sidorova et al. The study of the efficiency of micropulse transscleral cyclophotocoagulation in the combined treatment of patients with secondary neovascular glaucoma
Lam et al. Iris crystals in chronic iridocyclitis.
RU2207104C1 (ru) Способ лечения посттравматических и послеоперационных увеитов
RU2020137402A (ru) Способы лечения заболевания с использованием забуференных составов бевацизумаба
RU2259180C2 (ru) Способ лечения глазных проявлений заболеваний, передающихся половым путем
WO1998001137A1 (en) The ocular hypotensive active compositions
RU2395318C1 (ru) Способ лечения скрытых субретинальных неоваскулярных мембран
JP2024531861A (ja) Ｓｇｌｔ－２阻害剤を含む糖尿病性眼疾患の予防または治療用薬学的組成物
RU2481112C1 (ru) Способ лечения заболеваний роговицы, сетчатки и зрительного нерва у собак
RU2484795C2 (ru) Способ индукции задней отслойки стекловидного тела с помощью миниплазмина
US20040259844A1 (en) Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage
KR20230007245A (ko) 이미다졸 유도체를 포함하는 안질환의 예방 또는 치료용 조성물 및 이의 용도
WO2024249583A2 (en) Complement antibody-drug conjugates
JP2025517038A (ja) 黄斑浮腫又は網膜静脈閉塞の治療における使用のための単量体アネキシンａ５